13F Holdings
中文EN

RAPH Raphael Pharmaceutical Inc.

Medicinal Chemicals & Botanical Products · OTC · SEC CIK 1415397 · Fiscal year ends 12/31

Financial factors as of 2026-06-30 (2026Q2), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY33.4%
TTM EPS YoY-37.5%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE—
ROA-5,297.3%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets27,028.6%
Debt / equity—
Current ratio0.00x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.02x
Accruals ratio-5,216.2%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue—————
R&D expense$631,000$776,000$569,000$1.18M$776,000
SG&A expense$614,000$733,000$763,000$2.14M$853,000
Operating income-$1.25M-$1.51M-$1.33M-$3.32M-$1.63M
Net income-$1.28M-$1.52M-$1.34M-$3.36M-$1.62M
EPS (basic)0.070.080.080.230.15
EPS (diluted)0.070.080.080.230.15
Weighted avg. shares (diluted)19.55M18.67M16.72M14.34M11.17M
Balance sheet
Cash & equivalents$45,000$19,000$230,000$288,000$153,000
Receivables$2,000$2,000———
Current assets$51,000$25,000$237,000$331,000$422,000
PP&E, net$2,000$2,000$2,000——
Intangibles——$2,000$2,000—
Total assets$53,000$27,000$239,000$333,000$422,000
Current liabilities$1.49M$769,000$132,000$227,000$294,000
Short-term debt—$41,000———
Total liabilities$1.49M$769,000$132,000$227,000$294,000
Shareholders' equity-$1.43M-$742,000$107,000$106,000$128,000
Shares outstanding20.18M18.70M18.50M15.62M12.97M
Cash flow statement
Operating cash flow-$210,000-$532,000-$1.20M-$759,000-$1.42M
Capital expenditure———$2,000—
Free cash flow———-$761,000—
Investing cash flow———-$2,000—
Financing cash flow$236,000$321,000$1.15M$896,000$1.48M
Stock-based compensation$245,000$350,000$200,000$2.29M—

Free plan shows the latest 5 periods; Pro shows all 6 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.